

PRESS RELEASE

OB Pharmaceuticals, Inc. to Present at the Biotech Showcase™ Annual Conference on January 10, 2018

London, ON/January 5, 2018 – OB Pharmaceuticals, Inc. today announced that it will present at Biotech Showcase™ 2018, to be held January 8–10 during the most important week in healthcare at the Hilton San Francisco Union Square.

Dr. Larry Mahan, VP Business Development will present at the Biotech Showcase™ as follows:

Date: Wednesday January 10, 2018

Time: 10:00 a.m. (PST)

Room: Franciscan - C (Ballroom Level)

Venue: Hilton San Francisco Union Square Hotel, 333 O'Farrell Street, San Francisco, CA (United States)

OB Pharmaceuticals is developing first-in-class therapeutics for the prevention and management epilepsy. Our lead compound, TD561 shows particular promise in treating drug refractory epilepsy and seizures resulting from brain trauma with high potency and lack of discernible side effects in preclinical studies. “We are proud to be the only company presenting amongst the more than 240 private companies at Biotech Showcase 2018 with a focus on epilepsy therapeutic development,” stated John Poulter, CEO & President, “a disorder of significant unmet medical need.”

Biotech Showcase™, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.

Sara Demy-Colton, CEO of Demy-Colton, said: “We are delighted that OB Pharmaceuticals will be presenting at Biotech Showcase this year. Biotech Showcase is the perfect platform for life science companies to showcase their innovation and seek out their next deal. This year again we are thrilled to be hosting what we believe will be the great business development opportunity of 2018.”

About OB Pharmaceuticals:

OB Pharmaceuticals is a privately held early-stage Canadian biotechnology company founded in 2014 and is located in London, ON Canada. More information can be found at www.obpharmaceuticals.com.

Contacts:

John Poulter, CEO & President, jpoulter@icloud.com

Dr. Michael Poulter, CSO, mpoulter@obpharmaceuticals.com

Additional links and information:

Follow Biotech Showcase on Twitter: @EBDGroup and @Demy_Colton - #BiotechShowcase